mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing ...

周四，美银证券重申了对Krystal Biotech（NASDAQ:KRYS）的积极立场，维持买入评级，目标价为196.00美元。该公司目前市值50.7亿美元，根据 InvestingPro 分析，其财务健康状况获得"优秀"评级。此次评级确认是在Krystal ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

Chi - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and ...

In 2024, startups saw a notable resurgence in large-scale funding rounds. By May, over 100 startups had secured funding ...

Krystal Biotech (KRYS) clinical data updates for both KB408 and KB407, the Company’s clinical-stage, inhaled genetic medicine programs in Phase 1 for the treatment of rare respiratory diseases.

Citi analyst Samantha Semenkow maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) yesterday and set a price target of ...

along with its BEAM-302 base-editing candidate for alpha-1 antitrypsin deficiency (AATD) and BEAM-301, an in vivo lipid nanoparticle (LNP) therapy for glycogen storage disease 1a. Pfizer is ...

导读：2024年基因编辑疗法领域异象频出！从诺和诺德的三个月3笔加注,以及Ascidian公司与罗氏（Roche）约18亿美元针对神经疾病的RNA外显子编辑疗法的研究合作与许可协议，再到RNA编辑疗法在临床试验中的首次成功实现，医药巨头对于愈显潜力的 ...

周一，BMO Capital维持了Beam Therapeutics Inc (NASDAQ:BEAM)的"优于大市"评级和$57.00的目标价，该公司股票目前交易价格为$27.51。该股票交易价格远高于其52周低点$20.84，但显著低于高点$49.50。该公司的评论是在Beam Therapeutics管理层发布BEAM-101的额外临床数据和ESCAPE项目的临床前数据之后作出的。根据 ...

After hours: December 10 at 5:59:50 PM EST Loading Chart for KRRO ...